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Background: Dunnigan type Familial Partial Lipodystrophy (FPLD) is characterized by loss of subcutaneous fat
from the limbs and excessive accumulation on the visceral adipose tissue (VAT). Affected individuals have insulin
resistance (IR), diabetes, dyslipidemia and early cardiovascular (CV) events, due to their imbalanced distribution of
total body fat (TBF). Epicardial adipose tissue (EAT) is correlated with VAT. Hence, EAT could be a new index of
cardiac and visceral adiposity with great potential as a marker of CV risk in FPLD.
Objective: Compare EAT in FPLD patients versus healthy controls. Moreover, we aimed to verify if EFT is related
to anthropometrical (ATPM) and Dual-Energy X-ray Absorptiometry (DEXA) measures, as well as laboratory blood
findings. We postulated that FPLD patients have enlarged EAT.
Methods: This is an observational, cross-sectional study. Six patients with a confirmed mutation in the LMNA gene
for FPLD were enrolled in the study. Six sex, age and BMI-matched healthy controls were also selected. EFT was
measured by transthoracic echocardiography (ECHO). All participants had body fat distribution evaluated by ATPM and
by DEXA measures. Fasting blood samples were obtained for biochemical profiles and also for leptin measurements.
Results: Median EFT was significantly higher in the FPLD group than in matched controls (6.0 ± 3.6 mm vs. 0.0 ± 2.04
mm; p = 0.0306). Additionally, FPLD patients had lower leptin values. There was no significant correlation between EAT
and ATPM and DEXA measurements, nor laboratory findings.
Conclusions: This study demonstrates, for the first time, that EAT measured by ECHO is increased in FPLD patients,
compared to healthy controls. However, it failed to prove a significant relation neither between EAT and DEXA, ATPM
or laboratory variables analyzed.
Keywords: Lipodystrophy, Epicardial adipose tissue, Echocardiography, Metabolic syndrome, Dual energy x-ray
absorptiometryIntroduction
Lipodystrophies (LD) are clinically heterogeneous ac-
quired or inherited disorders characterized by general-
ized or partial loss of adipose tissue [1]. Familial Partial
Lipodystrophy, Dunnigan variety (FPLD) is a rare auto-
somal dominant disorder due to missense mutations in
the lamin A/C gene. It is phenotypically characterized by
the gradual loss of subcutaneous (SC) fat from the ex-
tremities and trunk, starting in puberty, with a selective* Correspondence: godoymatos@openlink.com.br
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girdle, neck and face [1-3].
In spite of being a rare condition, the better under-
standing of this underexplored pathology can reveal im-
portant clues to deciphering insulin resistance (IR) and
its metabolic consequences. FPLD patients have marked
IR with glucose intolerance (GI) or diabetes (DM), dys-
lipidemia, hepatic steatosis (HS), acanthosis nigricans
and a high risk of cardiovascular (CV) disease. Such risk
is similar to that described for visceral obesity, which is
associated with the development of metabolic syndrome
(MS) and its increased CV morbidity and mortality [2,3].entral. This is an Open Access article distributed under the terms of the Creative
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is, thus, a crucial matter for FPLD patients, as for obese
individuals [2,4]. Fat depot quantification has been studied
in FPLD [2,4-6]. Anthropometric (ATPM) methods are
limited in their ability to evaluate sites and extent of fat
deposition. However, waist circumference is widely ac-
cepted as a good predictor of VAT. Radiologic methods
like dual-energy x-ray absorptiometry (DEXA), computed
tomography (CT) and magnetic resonance imaging (MRI)
have been proved to be better tools to accurately measure
body fat depots. Unfortunately, CT requires radiation ex-
posure and, like MRI, is quite a high-cost method [2,4].
This later appears to be a reliable method and have also
been validated in FPLD, using both qualitative and quanti-
tative analysis [4-6]. A volumetric and single-slice MRI
adipose analysis using a novel fully automated segmenta-
tion method has been also recently validated [7]. However,
the high-cost limits its use. Several studies have reported
that the ECHO- assessed epicardial fat tissue (EFT) highly
correlates with VAT determined by MRI [8-10]. EAT
shares a common embryological origin with mesenteric
and omental fat. It might function as a lipid-storing depot,
as an endocrine organ secreting hormones, and as an in-
flammatory tissue secreting cytokines and chemokines.
Like VAT, ECHO-measured EFT is increased in visceral
obesity. Recent studies are testing the hypothesis that hu-
man EFT might contribute locally to the pathogenesis of
coronary atherosclerosis [10-13]. EFT can be visualized
and measured by transthoracic echocardiography, as first
proposed and validated by Iacobellis et al. [8]. Although
radiologic techniques can provide a volumetric and more
accurate measurement, echocardiographic assessment of
EFT certainly has the advantages of being inexpensive,
noninvasive, and readily available, accurate and reprodu-
cible method [8,9,11]. ECHO measurement of EFT has
been reported in HIV-Infected patients with highly active
antiretroviral therapy (HAART)-associated MS and LPD
[14]. It has also been validated in obese and MS patients
[8,11,15]. A recent meta-analysis evaluated the relation be-
tween EAT and MS, and concluded that EAT thickness is
significantly higher in patients with MS (standardized
difference in means 1.15, 95% confidence interval 0.78
to 1.53, p = 0.0001) [16]. Fernandez-Muñoz et al., have
tested the hypothesis that EFT is associated with VAT,
MS, and insulin resistance in postmenopausal women.
They showed that EFT has a strong correlation with BMI,
WC, and VAT, as well as with the presence of MS [17].
The present study is the first evaluating the EFT thickness
in FLPD subjects.
In this setting, the primary objective of the present
study was to provide original information about ECHO-
derived EFT measurement in FPLD subjects and to
assess its correlation with simple ATPM and DEXA mea-
sures. We postulate that FPLD patients have enlarged EFTmeasures, compared to their matched controls, in agree-
ment to ATPM and DEXA parameters.
Our secondary aim was to evaluate whether EFT
measures obtained by ECHO are related to leptin values,
as well as to glucose and lipid profiles, in affected
subjects.
Materials and methods
This is an observational, cross-sectional study held in
the Metabolism Department, an outpatient facility of the
State Institute of Diabetes and Endocrinology, IEDE (Rio
de Janeiro, Brazil). It was approved by our local ethics
committee and all subjects provided written, informed
consent.
Genetic assays
Mutational analysis of LMNA gene was carried out in 12
female patients with lipodystrophy phenotype, selected
from an outpatient facility. In six of them, mutations
known to be associated with FPLD were found. Three pa-
tients were heterozygote for the FPLD mutation LMNA
R482W and the other three patients had FPLD mutation
LMNA R482Q. Hence, six patients who had genetically
confirmed FPLD were selected for this study.
Exclusion criteria adopted were: not to be pregnant or
breast feeding; age <18 years; not to have acquired LPD
(auto-immune, AIDS or HAART linked); severe renal or
hepatic diseases; depression or alcoholism. Recent use of
thiazolidinediones (TZD), glucocorticoids, or significant
weight loss (≥3 Kg, in the last 3 months), were other ex-
clusion criteria.
Control volunteers were recruited and were age, gen-
der, and body mass index (BMI)-matched with the FPLD
subjects. All controls were healthy and had no previous
medical conditions likely to influence the evaluation at
the time of the study.
Anthropometry and body composition
ATPM and body composition measurements were per-
formed in all study participants, with the subject wearing
light clothing without shoes. For all subjects, weight and
height were measured to the nearest 0.5 kg and 0.5 cm,
respectively, and the BMI was calculated as weight (kilo-
grams) divided by height squared (square meters). Waist
circumference (WC) and hip circumference were also
measured by the same observer, and the waist-to-hip ra-
tio (WHR) was calculated.
Biochemical measurements
Blood samples were collected from all subjects after an
overnight fast (12 hours) between 0630 h and 0800 h.
Plasma glucose was determined by the glucose-oxidase
method. Cholesterol contents of lipoproteins fractions
and triglycerides were measured enzymatically. Plasma
Table 1 Descriptive and comparative anthropometrical,
echocardiography, DEXA and laboratory findings of FPLD
group vs. control group
FPLD (min-max) CONTR (min-max) P-VALUE
AGE (years) 36.95 (27.9-46.6) 35.45 (28.3-48.5) 0.8728
BMI (kg/m2) 22.85 (20.5-27.6) 22.05 (21.3-24) 0.3367
WHR 0.95 (0.8-1.04) 0.76 (0.7-0.87) 0.0163
EFT (mm) 6.0 (0-8) 0.0 (0-5) 0.0306
TBF (%) 17.4 (16.1-27.6) 39.15 (32.2-45.2) 0.0039
FMR 1.17 (0.70-2.91) 0.64 (0.47-0.82) 0.0104
A/G R 1.19 (0.8-1.49) 0.82 (0.67-1.06) 0.0163
FG (mg/dl) 90 (75-115) 83.5 (74-98) 0.298
G2h (mg/dl) 117 (108-213) 99.5 (74-134) 0.1735
INS (pmol/L) 10.7 (4.8-42.8) 6.6 (2-15.8) 0.2623
HOMA-IR 2.46 (0.91-12.14) 1.25 (0.36-3.81) 0.2002
LEPTIN (ng/ml) 4.4 (2.4-7.3) 16.75 (6.1-30.1) 0.0131
TC (mg/dl) 213 (186-264) 218 (156-283) 0.631
LDL (mg/dl) 139.5 (102-163) 118.5 (82-207) 0.5218
HDL (mg/dl) 39.5 (29-43) 65 (46-91) 0.0039
TG (mg/dl) 203.5 (129-321) 110 (52-212) 0.0782
Abbreviations: familial partial lipodystrophy, Dunnigan type group [FPLD];
Dual-Energy X-ray Absorptiometry [DEXA]; control group [CONTR]; epicardial
fat tissue [EFT]; p-value [p]; body mass index [BMI]; waist-to-hip ratio [WHR];
total body fat [TBF%]; android/ginecoid ratio [A/G R]; fat mass ratio [FMR],
fasting glucose [FG]; 2-h post load glucose [G2h]; total cholesterol [TC];
LDL- cholesterol [LDL]; HDL-cholesterol [HDL]; VLDL-cholesterol [VLDL];
triglycerides [TG].
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radioimmunoassay. Fasting and 2-h postload glucose
(G 2 h) levels after 75-g oral glucose tolerance test
(OGTT) were determined. Insulin resistance (IR) was
estimated through the homeostasis model assessment
(HOMA-IR), using the formula: IR = fasting insulin ×
fasting glucose/22.5.
Dual-energy x-ray absorptiometry
Whole body fat assessment by DEXA was performed
using GE Lunar Prodigy Advance software, version 9.5,
LNR 41569 model (GE Lunar Corp., Madison, WI),to
determine fat and lean soft-tissue mass in the trunk and
legs, in FPLD patients and their matched normal healthy
controls. The android/gynoid ratio [A/G R] and central
to peripheral fat Ratio (or Fat Mass Ratio [FMR]) was
used to investigate body fat distribution [18].
Echocardiographic Study
Each subject underwent transthoracic two-dimensional
guided M-mode ECHO. ECHO was performed with a
Siemens SONOLINE Omnia instrument (Issaquah, WA),
by standard techniques, with subjects in the left lateral de-
cubitus position. ECHO were preliminarily read by a first
reader and recorded for future revaluation. Subsequently
they were reread by another experienced reader. Both
readers were blinded to subjects’ anthropometric features.
The EFT appears as an echo-free space and was measured
on the free wall of the right ventricle from both paraster-
nal long- and short-axis views, as previously described by
Iacobellis et al. [8,14].
Statistical analysis
Analysis was undertaken using BioEstat (Belém, PA) and
p-value less than 0.05 was considered statistically signifi-
cant for all analyses. All variables were expressed as con-
tinuous. Descriptive statistics are presented as the median
and standard error in tables. Non-parametric tests were
performed, because of the non-Gaussian distribution of
the variables, data dispersion and the lack of symmetry of
the reduced size sample.
Comparison between the FPLD vs. the control group
was provided by Mann-Whitney tests. The variable in-
teractions were tested for significance with Spearman
tests, as follows: between EFT and each of the DEXA pa-
rameters; EFT and BMI, waist-to-hip ratio (WHR) and
age, as well as with EFT and laboratorial findings (leptin,
fasting glucose [FG], 2hG, total cholesterol [TC], HDL,
LDL, VLDL and HOMA-IR).
Results
Table 1 summarizes ECHO, biochemical, ATPM and
DEXA measures of the 12 female patients enrolled in this
study. There was no significant difference in age (p = 0.87)or BMI (p > 0.05) between FPLD patients and controls.
Median EFT was significantly increased in FPLD subjects
(p = 0.0306).
FPLD patients also had ATPM and DEXA markers of
increased central abnormal fat accumulation and less per-
ipheral fat, noticeably by higher WHR (p = 0.0163) and
android/ginoid ratio [A/G R] (p = 0.0163), as well as by
decreased total body fat [TBF%] (p = 0.0039) and increased
fat mass ratio [FMR] (p = 0.0104).
The biochemical parameters are also displayed in
Table 1. As for laboratory findings, we observed that
HDL-cholesterol (p = 0.0039) and leptin (p = 0.0131) were
expressively lower in the FPLD group than in the control
group. These laboratorial findings reinforce the unfavor-
able metabolic profile, related to the impaired peripheral
fat distribution patterns, in FPLD patients, as previously
reported in the literature.
Observing that FPLD patients had increased EFT, in
agreeance to DEXA and ATPM parameters, as expected,
one could propose a likely relation between EFT and
ATPM and DEXA. However, even though merely descrip-
tive and comparative data would suggest such a statement,
it was refuted by Spearman Correlation tests, as shown
in Table 2.
Table 2 Spearman Coefficient (rs) relations between
Epicardial Fat Tissue (EFT) and anthropometric (Age, BMI
and WHR), DEXA (TBF, A/G R and FMR) and laboratory
variables
Age BMI WHR TBF% A/G R FMR FG
rs 0.56 0.18 0.68 0.29 0.68 0.03 0.44
p 0.25 0.73 0.14 0.57 0.14 0.96 0.38
G2h Insulin TC LDL HDL TG Leptin
rs 0.07 0.0003 0.15 0.24 −0.44 −0.26 0.60
p 0.89 ns 0.78 0.65 0.38 0.61 0.21
Abbreviations: epicardial fat tissue [EFT]; Spearman coefficient [rs]; p-value [p];
body mass index [BMI]; waist-to-hip ratio [WHR]; total body fat [TBF%]; android/
ginecoid ratio [A/G R]; fat mass ratio [FMR]; fasting glucose [FG]; 2-h post load
glucose [G 2h]; total cholesterol [TC]; LDL- cholesterol [LDL]; HDL-cholesterol
[HDL]; triglycerides [TG].
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Although several reports have been performed evaluat-
ing ectopic fat depots in patients with FPLD and LMNA
mutations, this study was the first to test the hypothesis
that EFT thickness is increased in FPLD patients [19,20].
This observation is in accordance to previous findings in
other conditions in literature, such as central obesity,
coronary artery disease (CAD), type 2 diabetes mellitus
(T2D), and MS [16,21]. Our patients had increased EFT,
in agreement with prior results evaluating VAT in patients
with FPLD [19,20]. Nonetheless, although our patients
had increased EFT, as well as ATPM and DEXA parame-
ters suggestive of less peripheral fat deposition, no statis-
tical relation between these variables was found, in
opposition to what we expected. We attribute the lack of
significance of these relations to our limited size sample
(Type 2 statistic error). Otherwise, it has been demon-
strated that there is a good correlation between pericardial
fat measured by echocardiography and anthropometric
parameters of metabolic syndrome [21,22].
Furthermore, recent reports have suggested threshold
values of EAT associated with metabolic and ATPM risk
factors. Cut-off points for EAT thickness have been pro-
posed to diagnose MS [21,22]. Okyay et al. reported that
EAT thickness of > 4.35 mm indicated MS according to
the International Diabetes Federation [22]. In our study,
median EFT in FPLD patients was 6.0 ± 3.6 mm versus
0.0 ± 2.04 mm in matched control subjects. These results
are in agreement with data recently published in MS pa-
tients in whom mean EFT thickness was 5.8 + 1.9 mm [15].
Additionally, it has been suggested that EFT thickness,
an indicator of cardiac adiposity, may be significantly
related to inflammatory adipocytokines (plasma visfatin
and plasminogen activator inhibitor-1 levels) in visceral-
obese patients, reinforcing that EFT might be used as an
easy and reliable marker of VAT and inflammation and
as a cardiovascular risk indicator [10,23].Hence, EAT could be a promising marker of VAT accu-
mulation, and ECHO could be a cost-effective technique
for the diagnosis of FPLD and its treatment management.
Determining EFT could also be useful for therapeutic in-
terventions with drugs that could modulate EFT paracrine
activity in the heart [24]. There are few studies evaluating
drug interventions on epicardial fat. Thiazolidinediones
improve fat metabolism and reduce systemic inflammation
through their actions as peroxisomal proliferator activating
receptor-gamma (PPAR-gama) agonists. Pioglitazone re-
duced the expression of interleukins in epicardial adipose
tissue of MS and Type 2 Diabetes [25]. Data about epicar-
dial fat are limited, but it has also been showed that ator-
vastatin reduced EAT in coronary artery disease (CAD)
patients [26]. There are no studies evaluating pharmaceut-
ical interventions on EFT in patients with FLPD. Apart
the good perspectives, nevertheless, one should attempt
for observer-dependent reproducibility of this technique,
that could be a limitation to its widely use [27].
Regarding EFT adipocytokine production, our findings
revealed a marked hypoleptinemia in FPLD patients ver-
sus their controls. Positive associations between leptin and
TBF% were found, which indicates, as expected, that lower
peripheral fat deposition correlates well with lower leptin
values. Hypoleptinemia has been incriminated in ectopic
fat deposition, lipotoxicity and hyperphagia, as well as in-
duced increased energy expenditure in FPLD affected sub-
jects [28]. Nevertheless, these pathological features could
be ameliorated in response to leptin replacement therapy,
with promising results in the lipid and glucose metabol-
ism, through the IR reduction [29].
Interestingly, leptin can be considered one of the com-
mon denominators of IR in LD and obesity. Remarkably,
leptin lies at the interface of lipodystrophy and obesity
[30]. Hence, better understanding of FPLD, a natural
single-gene model of MS, could be the key to unlock
leptin resistance in obesity, allowing leptin to perform
its insulin-sensitizing function.
It could be hypothesized that higher EAT thickness might
be implicated in the pathophysiology of the MS (and maybe
FPLD), because it, as an endocrine organ, produces a num-
ber of factors that influence insulin sensitivity. However, it
appears more plausible to assert that higher EAT thickness
may serve as an indicator of visceral fat accumulation.
In summary, we present a cross-sectional study on the fat
distribution pattern of FPLD patients and demonstrate that
EFT is increased in these individuals, compared to matched
controls. It would be of interest to examine larger numbers
of affected FPLD patients to confirm the previously observed
relationship between EFT and VAT. Further detailed studies
are needed to conclusively address these topics and unravel
underlying mechanisms that could link FPLD to IR. In con-
clusion, the better understanding of FPLD could provide
novel insights for interventions in MS and obese patients.
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